Medisafe 1 Technologies demonstrates syringe locking device at Israel's National Ministry of Health

NewsGuard 100/100 Score

Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company conducted an official demonstration of its barcoded syringe locking device at Israel's National Ministry of Health.

Several government officials were present at the demonstration including Deputy Minister Yaakov Litzman. Attendees from the ministry expressed their optimism for the implementation of the device at the nation's hospitals, and invited Medisafe 1 Technologies for a follow-up meeting with ministry professionals serving in operational capacities.

In addition, attending ministry officials discussed the possibility of adding the syringe safety technology to Israel's nationwide Pharmaceuticals Program. Admittance to the program would grant federal subsidies for the implementation of the technology.

The Health Ministry is officially headed by Prime Minister Benjamin Netanyahu.

"Our demonstration impressed upon the ministry the importance of electronically confirming the administration of a particular medicine or dosage to a patient, and the life-saving benefits of physically preventing the administration of an incorrect medicine or dosage," said, Jacob Elhadad, CEO of Medisafe 1 Technologies.

"We would like to thank the attending ministry officials including the Deputy Minister for their consideration and enthusiasm, and we look forward to our follow-up meeting with the professionals responsible for the nationwide implementation of medical technologies."

Source:

Medisafe 1 Technologies Corp.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MGI Enters Strategic Partnership with Prepaire Labs to Advance Drug Discovery and Precision Medicine